

AD-A160 237

SEQUENCE POLYMORPHISM OF HLA-DR BETA 1 ALLELES RELATING
TO T CELL-RECOGNIZED DETERMINANTS(U) MINNESOTA UNIV
MINNEAPOLIS J S CAIRNS ET AL. 198 N00014-85-K-0004

1/1


UNCLASSIFIED

F/G 6/3

NL



END
FILMED
DTIC



MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS - 1963 - A

2

AD-A160 237

SEQUENCE POLYMORPHISM OF HLA-DRB1 ALLELES
RELATING TO T CELL-RECOGNIZED DETERMINANTS

J.S. Cairns, J.M. Curtsinger, C.A. Dahl,
S. Freeman, B.J. Alter, and F.H. Bach.

Immunobiology Research Center
Departments of Laboratory Medicine/Pathology and Surgery
Box 724 Mayo Building
University of Minnesota
Minneapolis, Minnesota 55455.

This is paper #421 from the Immunobiology Research Center, University of Minnesota, Minneapolis, Minnesota 55455. This publication was supported by the Harry Kay Charitable Foundation, NIH grants AI 17687, AI 18326, AI 19007, and contract O.N.R./N00014-85-K-0004.

DTIC FILE COPY

DTIC
ELECTE
OCT 11 1985
S D
E

INTRODUCTION

HLA class II molecules are a highly polymorphic family of dimeric cell surface proteins primarily involved in regulating T cell responses to extrinsic antigens. To define regions of class II molecules involved in T cell recognition, we have compared sequences of three HLA-DR β cDNA clones obtained from cells that all express the same serologically defined determinants but differ in terms of T cell-recognized specificities. The comparisons indicate that very few (one to four) nucleotides differ between what are almost certainly alleles of the DR β locus. All differences were in the first domain of the molecule and all localized to a region from amino acids 71-86. Since all differences were found only in this region of the molecule, and since DR α chains seem to be relatively nonpolymorphic¹, these positions in the DR β chain must play a major role in influencing T cell recognition of the DR molecule.

Serological and molecular cloning experiments have shown that there are three families of class II molecules within the HLA complex, termed DP, DQ, and DR. For the DR4-DRw53 haplotype which we have studied, within the DR family, one α and three complete β genes are known; one β gene is a pseudogene². At least two DR $\alpha\beta$ dimers are expressed. The serologic determinant DR4 is associated with the α 1 dimer whereas the DRw53 determinant is associated with the α 2 dimer. To date, comparisons of DR β nucleic acid sequences have been made between cells differing both serologically and in terms of T lymphocyte recognized determinants, making it impossible to ascribe determinants recognized by T lymphocytes to particular polymorphic sequences. To minimize differences to those potentially involved in T cell recognition, we have compared sequences of what appear to be DR β 1 cDNA clones from cells which differ with respect to determinants, designated as "Dw", recognized by

allogeneic T cells, but share the serologically-defined specificity DR4.

Among cells which express DR4, at least 5 distinct Dw subtypes have been defined, designated Dw4, Dw10, Dw13, Dw14, and Dw15.³ Clones LS5.8.1 and S3.4 were obtained from cDNA libraries of two homozygous typing cells (HTCs), LS40 and SST0, expressing Dw14 and Dw13 respectively. The sequences of these clones are shown in Fig. 1. These clones differ by a single nucleotide resulting in an alanine in LS5.8.1 (Dw14) and a glutamic acid in S3.4 (Dw13) at amino acid position 74 (table 1, lines a and b).

LS5.8.1 differs by only three nucleotides (two amino acids, table 1, lines a & c) from an unpublished DR β sequence (Long, Mach et al., personal communication), from a DR4+ cell, referred to as "DR4,6". To make this sequence comparison more meaningful, we used cloned cytotoxic T lymphocytes that differentiate between the DR products (most likely DR β 1)⁴ of Dw4 and Dw14, and established that DR components of Dw4 are associated with the DR4 haplotype of "DR4,6". As shown in table 2, both LS40 and "DR4,6" served as effective targets for cloned CTL which recognize both Dw4 and Dw14 associated determinants; only "DR4,6" was lysed by cloned CTL recognizing Dw4 but not Dw14 determinants.

Based on the high degree of sequence homology between the DR β clones from Dw14, Dw13, and Dw4 cells described, it is extremely likely that these clones represent transcripts of alleles of a single locus. These clones presumably represent transcripts of the DR β 1 locus for the following reasons. Speis, Strominger et al.⁵ have compared sequences of the first domains of known (based on amino acid sequencing of characterized proteins) DR β 1 and DR β 2 genomic clones from Priess (a DR4-Dw4 HTC) and have found 19 amino acid differences between them. The DR4-Dw4 β 1 sequence from Priess is identical to the sequence of "DR4,6".

On allelic sequences, because they differ by 2 to 3 amino acids from the DR β 1 sequence of Priess, but by 16 to 17 amino acids from the DR β 2 sequence, most likely represent DR β 1 sequences. Also apparent from this comparison is that at the positions where the DR β 1 sequences of Dw14, Dw13, and Dw4 differ from each other, one of the alternative amino acids and the corresponding codon is also present at the same position in the DR β 2 sequence. Whether this has occurred as the result of accumulated mutation in the DR β 1 gene, or as a result of a gene conversion-like mechanism, is not clear.

The conclusion that these sequences represent DR β 1 transcripts is also consistent with the observation that there is an approximately ten-fold higher level of DR β 1 as compared with DR β 2 expressed on the surface of EBV-transformed B cells^{5,6}; that finding may well be reflected in levels in the mRNA pool. We have now sequenced all or part of three different DR β cDNA clones from our LS40 library and, although there is evidence to suggest that transcripts of this gene are differentially processed (Cairns, S., Dahl, C., Curtsinger, C., and Bach, F.H., in preparation) all are apparently transcripts of a single locus. The clone sequenced by Long et al. also is a member of a highly represented family of DR β clones (group 2 in reference 7).

Based on the likelihood that these sequences represent transcripts of the DR β 1 locus, it is apparent from these data that a few amino acid differences may profoundly affect how the molecule is recognized by T lymphocytes. This situation is not without precedent; relatively minor amino acid substitutions in the heavy chain of the HLA-A2 molecule^{8,9} and in mutants of the K^b molecule¹⁰ drastically alter T cell recognition of those molecules.

Structural models of the DR molecule have placed residues 71, 74, and 86 on the outer face of the DR molecule¹¹. Residues 71 and 74 are included in the third hypervariable region of the DR β chain, the only proposed α -helical

region in the first domain¹¹. Amino acid substitutions in the I-A mutant, bml2 are in this same region¹². To the extent that determinants of the DR β 1 dimer are involved in restricted recognition of foreign (nominal) antigens, for which there is some evidence^{13,14}, these same amino acid differences among alleles of DR β 1 must be involved.

Whether the changes in DNA sequence noted in this paper are directly responsible for encoding T cell recognized determinants or whether they are responsible for conformational changes involving other parts of the molecule which are recognized by T cells is not addressed by this approach. We would expect, in addition, to find other sequence differences that could result in determinants recognized by T cells. We would postulate, however, as we have recently discussed^{15,16}, that the allelic differences reported here in a naturally evolving population may be of primary importance evolutionarily and functionally for T lymphocyte recognition.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Avail and/or	
Dist	Special
A-1	



REFERENCES

1. Crumpton, M.J., Bodmer, J.G., Bodmer, W.F., Heyes, J.M., Lindsay, J., and Rudd, C.E. In: *Histocompatibility Testing 1984* (Ed.: E. Albert) Munksgaard, Copenhagen, p. 29-37.
2. Larhammar, D., Servenius, B., Rask, L., and Peterson, P. *Proc. Natl. Acad. Sci.* 82:1475-1479, 1985.
3. Reinsmoen, N.L., and Bach, F.H. *Hum. Immunol.* 4:249-258, 1982.
4. Reinsmoen, N.L., and Bach, F.H. (Submitted).
5. Spies, T., Sorrentino, R., Boss, J.M., Okada, K., and Strominger, J.L. *Proc. Natl. Acad. Sci.* 1985, (In press).
6. Yabe, T., Suzuki, M., Satake, M., Juji, T., and Hamaguchi, H. *Immunogenetics* 20, 155-167, 1984.
7. Long, E.O., Wake, C.T., Gorski, J., and Mach, B. *EMBO*, 2:389-394, 1983.
8. Biddison, W.E., Ward, F.E., Shearer, G.M., and Shaw, S. *J. Immunol.* 124:548-552, 1980.
9. Goulmy, E., van Leeuwen, A., Blokland, F., van Rood, J.J., and Biddison, W.E. *J. Exp. Med.* 155:1567-1572, 1982.
10. Nairn, R., Yamaga, K., and Nathenson, S.G. *Annu. Rev. Genet.* 14:241-277, 1980.
11. Norcross, M.A., and Kanehisa, M. *Scand. J. Immunol.* 1985, (In press).
12. McIntyre, K.R., and Seidman, J.G. *Nature* 308:551-553, 1984.
13. Reinsmoen, N.L., Volkman, D.J., Bach, F.H., and Fauci, A.S. *Federation Proc.* 43:1819, 1984, (abstract).
14. Qvigstad, E., Thorsby, E., Reinsmoen, N.L., and Bach, F.H. *Immunogenetics* 20:583-588, 1984.
15. Nicklas, J.N., Noreen, H.N., Segall, M., and Bach, F.H. *Hum. Immunol.* 13:95, 1985.

16. Bach, F.H. *Immunol. Today* 6:89-94, 1985.
17. Dale, R., McClure, B., Houchins, J.P. *Plasmid* 13:13-40, 1985.
18. Sanger, F., Nicklen, S., and Coulson, A.R. *Proc. Natl. Acad. Sci.*
74:5463, 1977.

ACKNOWLEDGMENTS

We would like to thank Drs. J. Strominger and E. Long for making unpublished data available and Dr. E. Long, Prof. B. Mach and Prof. P. Peterson for their donation of DR β cDNA clones. S. Cairns is indebted to Drs. D. Larhammar, L. Rask, B. Laurent and Prof. Peterson and B.J. Alter expresses her thanks to Dr. Tomi Meo for assistance during initial stages of this investigation. We thank Ms. N. Andresen for typing this manuscript.

LS5.8.1 5'TCCCTGAGTGAGACTCACCTGCTCCTCTGGCCCTGGTCCCTGCTCCCTGCTCCAGC ATG GTG TGT CTG AAG TTC 74

start

M V C L K F

P G G S C M A A L T V T L M V L S S P L
 CCT GGA GGC TCC TGC ATG GCA GCT CTG ACA GTG ACA CTG ATG GTG CTG ACC TCC CCA CTG 134

-1 +1 10
 A L A G D T R P R F L E Q V K H E C H F
 GCT TTG GCT GGG GAC ACC CGA CGT TTC TTG GAG CAG GTT AAA CAT GAG TGT CAT TTC 194

S3.4

20 30
 F N G T E R R V R F L D R Y F Y H Q E E Y
 TTC AAC GGG ACG GAG CAG CCG GTG CCG TTC CTG GAC AGA TAC TTC TAT CAC CAA GAG GAG TAC 254

40 50
 V R F D S D V G E Y R A V T E L G R P D
 GTG CGC TTC GAC AGC GAC GAC GTG GGG GAG TAC CCG CCG GTG ACC GAG CTG GGG CGG CCT GAT 314

60 70
 A E Y W N S Q K D L L E Q R R A A V D T
 GCC GAG TAC TGG AAC AGC CAG AAG GAC CTC CTG GAG CAG AGG CGG GCC GCG GTG GAC ACC 374

80 90
 Y C R H N Y G V V E S F T V Q R R V Y P
 TAC TGC AGA CAC AAC TAC GGG GTT GTG GAG AGC TTC ACA GTG CAG CGG CGA GTC TAT CCT 434

100 110
 E V T V Y P A K T Q P L Q H H N L L V C
 GAG GTG ACT GTG TAT CCT GCA AAG ACC CAG CCC CTG CAG CAC AAC CTC CTG GTC TGC 494

120 130
S V N G F Y P G S I E V R T F R N G Q E
TCT GTG AAT GGT TTC TAT CCA GGC AGC ATT GAA GTC AGG TGG TTC CGG AAC GGC CAG GAA 554

140 150
E K T G V V S T G L I Q N G D W T F Q I
GAG AAG ACT GGG GTG GTG TCC ACA GGC CTG ATC CAG AAT GGA GAC TGG ACC TTC CAG ACC 614

160 170
L V M L E T V P R S G E V Y T C Q V E H
CTG GTG ATG CTG GAA ACA GTT CCT CGG AGT GGA GAG GTT TAC ACC TGC CAA GTG GAG CAC 674

180 190
P S L T S P L T V E W R A R S E S A Q S
CCA AGC CTG ACG AGC CCT CTC ACA GTG GAA TGG AGA GCA CGG TCT GAA TCT GCA CAG AGC 734

200 210
K M L S C V G G F V L G L L F L G A G L
AAG ATG CTG AGT GGA GTC GGC GGC TTC GTG CTG GGC CTT TTC CTT GGG GCC GGC CTG 794

220 230
F I Y P R N Q K G H S G L Q P T G F L S
TTC ATC TAC TTC AGG AAT CAG AAA GGA CAC TCT GGA CTT GGA CCA ACA GGA TTC CTG AGC 854

stop
TGAAGTGAAGATGACCCACATTCAAGGAAGAACCCTTCTGCCCCAGCTTTCAGGATGAACACTTCCCGCTTGGCTCTC 933
ATTCTTCCACAAGAGAGACCTTCTCCGGA CCTGGTTGCTACTGGTTCCAGCAGCTCTGCCAGAAAATGTCCCTCCCTTGTG 1012
GCTGCCCTCAGCTCGTACCTTTGGCCCTGAAGTCCCAGCATTAAATGGCAGCCCTCATCTTCCAAGTTTGTGCTCCCCCTT 1091
TACCTAATGCTTCCCTCCCATGCACTGTACTCTGCTGTGCCACAAACANATTACATTATTAATGTTTCTCAAA 1170
CATGGAGTTAA 3'

Legend to Figure 1.

Both LS5.8.1 and S3.4 were initially isolated from cDNA libraries constructed from membrane-bound (LS5.8.1) or cytoplasmic (S3.4) RNA. cDNA was synthesized using oligo-dT to prime the first strand, and nascent mRNA nicked with RNase H to prime the second strand. cDNA was "blunt-ended" with DNA polymerase and tailed with dCTP using terminal deoxynucleotidyltransferase. cDNA was annealed with Pst 1-cut, dG-tailed pUC9, and introduced into *E. coli* strain 83. Each library, which contained approximately 7000 colonies was screened with a 790 bp Sst1-HindIII fragment of a DR β cDNA clone isolated by E. Long et al.⁷. This probe contains nearly the entire coding region from this clone and under the conditions of hybridization employed, reacts most strongly with DR β cDNA but also reacts weakly with DP β and DQ β . The inserts from these clones, or fragments thereof, were subcloned into the single-stranded vector M13mp19. Subclones were either sequenced directly or truncated subclones were generated by the method of Dale et al.¹⁷. Sequencing was done using the dideoxy chain termination method¹⁸. "N's" in the S3.4 sequence represent unsequenced areas of the insert. In addition, approximately 110 nucleotides at the 5' end of this insert have not yet been sequenced. Where the sequence of S3.4 is identical to that of LS5.8.1, a dash is shown below the LS5.8.1 sequence.

Table 1. Summary of amino acid differences between DR β 1 alleles.

	clone	cell	DR	Dw	<u>amino acid position</u>	
					71	74
a.	LS5.8.1	LS40	β 1	14	Arg	Ala
b.	S3.4	SSTO	β 1	13	Arg	Glu
c.		"DR4,6" ¹	β 1	4	Lys	Ala
d.		Preiss ²	β 1	4	Lys	Ala
e.		Preiss ²	β 2	4	Arg	Glu

¹Taken from the unpublished sequence of a DR β cDNA clone obtained by E. Long, B. Mach and coworkers.

²Taken from T. Speiss et al.⁵.

Table 2. Lysis of "DR4,6", LS40 and other targets by cytotoxic T lymphocyte clones.

clone ^x	Target				
	<u>"DR4/6"</u>	<u>LS40</u>	<u>BO (Dw4 HTC)</u>	<u>K.Blo (Dw3,4)</u>	<u>J.Nor (Dw2,3)</u>
KD15	43.0 ± 4.4 [†]	0.8 ± 1.4	35.7 ± 4.6	40.5 ± 6.3	2.1 ± 1.3
KD33	59.2 ± 6.6	2.1 ± 1.2	27.2 ± 3.9	40.0 ± 2.8	10.1 ± 2.0
KD48	55.4 ± 8.3	56.3 ± 9.5	16.1 ± 2.7	23.4 ± 2.7	1.1 ± 2.5

^x KD15 and KD33 are Dw4 specific; KD48 lyses Dw4 and Dw14 targets⁴.

[†] % CML ± S.D. The effector:target ratio is 20:1.

Legend to Table 2

The cell-mediated lympholysis (CML) assay was performed as follows. Target cells were labeled with 0.25 mCi chromium 51 for 1 hour, washed 3 times with cold RPMI-1640 containing 20% pooled human serum, and adjusted to 1×10^4 cells/ml. The cloned effectors were resuspended in IL-2-free culture medium the day prior to testing. Effectors were adjusted to the appropriate concentration and 100 μ l effectors + 100 μ l targets were added to V bottom microtiter plates, spun at 500 rpm for 5 minutes and incubated in a 37°, 5% CO₂ humidified environment for 4 hours. The plates were then spun at 1000 rpm for 10 minutes and 150 μ l of supernatant were aspirated and placed in scintillation vials. Ready-Solv[™] HP (Beckman 566436) (2.5 ml.) was added to each vial and the samples were counted in a β scintillation counter. Spontaneous release of ⁵¹Cr was assessed by incubating target cells without effector cells and maximum release of the isotope was assessed by incubating target cells with 0.1% hexadecyltrimethylammonium bromide. Results were calculated as follows:

$$\text{percent cytotoxicity} = \frac{\text{cpm experimental wells} - \text{cpm spontaneous release}}{\text{cpm maximum release} - \text{cpm spontaneous release}} \times 100$$

END

FILMED

11-85

DTIC